© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Trevi Therapeutics, Inc. (TRVI) shows an Average True Range (ATR) of 0.76 and an Enterprise Value of 151.69M. Its average trading volume over the past 3 months is 1.86M, indicating liquidity. These fundamental metrics provide insight into TRVI's underlying financial health and market activity.
Trevi Therapeutics, Inc. (TRVI) technical indicators as of December 22, 2025: the SMA 20 is 1.66%, SMA 50 at 11.71%, and SMA 200 at 60.24%. The RSI 14 value is 56.49, suggesting its current momentum. These technical analysis signals help assess TRVI's price trends and potential future movements.
Trevi Therapeutics, Inc. (TRVI) stock performance overview as of December 22, 2025: The 52-week high is $14.39 (currently -9.59% below), and the 52-week low is $3.47 (currently 274.77% above). Over the past year, TRVI's performance is 211.99%, compared to the S&P 500's 12.87% change.
According to market data, Trevi Therapeutics, Inc. (TRVI) stock's recent performance metrics show that over the last month, TRVI is 15.03%, with a Year-to-Date (YTD) performance of 215.78%. Over the past year, the stock has seen a 211.99% change. These figures summarize TRVI's price movements across various periods, reflecting its historical returns.
According to current financial data, TRVI stock's P/E (TTM) ratio is -40.26, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for TRVI, including P/S (11176.21), P/B (9.73), and P/FCF (-28.38), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.